Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom improvement
RCT	64 men with NIH category 3A chronic pelvic pain syndrome	Proportion of men with decrease in National Institutes of Health-Chronic Prostatitis Symptom Index (NIH-CPSI) score of 25% or more 6 weeks 78% with celecoxib 31% with placebo Absolute numbers not reported	P <0.02	Effect size not calculated	celecoxib
RCT	64 men with NIH category 3A chronic pelvic pain syndrome	Proportion of men with decrease in NIH-CPSI score of 25% or more 8 weeks 31% with celecoxib 19% with placebo Absolute numbers not reported	Reported as significant P value not reported	Effect size not calculated	celecoxib
RCT	64 men with NIH category 3A chronic pelvic pain syndrome	Proportion of people with Subjective Global Assessment (SGA) improvement of 25% or more 6 weeks 56% with celecoxib 41% with placebo Absolute numbers not reported	Significance not assessed
RCT	64 men with NIH category 3A chronic pelvic pain syndrome	Proportion of people with SGA improvement of 25% or more 8 weeks 28% with celecoxib 22% with placebo Absolute numbers not reported	Significance not assessed
RCT	64 men with NIH category 3A chronic pelvic pain syndrome	Proportion of people with SGA improvement of 50% or more 6 weeks 38% with celecoxib 13% with placebo Absolute numbers not reported	Significance not assessed
RCT	64 men with NIH category 3A chronic pelvic pain syndrome	Proportion of people with SGA improvement of 50% or more 8 weeks 13% with celecoxib 6% with placebo Absolute numbers not reported	Significance not assessed